Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0837 • ACR Convergence 2023
A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis
Matthew Baker¹, Sarah Kavanagh², Stanley Cohen³, Alan Matsumoto⁴, Ara Dikranian⁵, John Tesser⁶, Alan Kivitz⁷, Konstantinos Alataris⁸ and Mark Genovese⁹, ¹Stanford University, Menlo Park, CA, ²Kavanagh Statistical Consulting, LLC, Apex, NC, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Arthritis and Rheumatism Associates, Wheaton, MD, ⁵Cabrillo Center for Rheumatic Disease, San Diego, CA, ⁶Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Nēsos, Menlo Park, CA, ⁹Stanford University, Sunnyvale, CA
Background/Purpose: Vagus nerve stimulation (VNS) has emerged in recent decades as a potential therapy for RA.We have previously shown that auricular VNS produced an average…
Abstract Number: 0985 • ACR Convergence 2023
Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry
Daniel Solomon¹, Fredrik Johansson², Hongshu Guan³, Leah Santacroce⁴, Lin Guo⁵, Wendi Malley⁵ and Heather Litman⁵, ¹Brigham and Women's Hospital, Newton, MA, ²Chalmers University of Technology, Goteborg, Sweden, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵CorEvitas, LLC, Waltham, MA
Background/Purpose: Comorbid conditions are very common in rheumatoid arthritis (RA) and several prior studies have derived comorbidity clusters using machine learning (ML). Clustering using ML…
Abstract Number: 1047 • ACR Convergence 2023
Infrared Thermography Imaging Discriminates Between Inflamed and Non-inflamed Joints
Maria I. ("Maio") Danila¹, Giovanna Rosas², Fenglong Xie², Jeffrey R Curtis³, Kiara Aaron², Stephanie Ford² and Laura Hughes⁴, ¹University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁴University of Alabama at Birmingham; East Alabama Medical Center, Birmingham, AL
Background/Purpose: Infrared thermography (IRT) is an emerging technology that has the potential to rapidly assist in identifying joint inflammation in patients with joint symptoms. However,…
Abstract Number: 1267 • ACR Convergence 2023
Lower Herpes Zoster Rate of Tocilizumab and Tofacitinib in Patients Undergoing Treatment for Rheumatoid Arthritis
Yao fan Fang¹, Lai-Chu See² and Shu-Hao Chang², ¹Chang-Gung Memorial Hospital – Linkou, Taoyuan, Taiwan, ²Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan City, Taiwan
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) have become the primary treatment option for rheumatoid arthritis (RA) from 2010 in Taiwan. Tocilizumab is an interleukin-6 receptor…
Abstract Number: 1283 • ACR Convergence 2023
Atherogenic Index of Plasma Identifies Patients with Rheumatoid Arthritis and Increased Carotid Intima-Media Thickness
Dionicio A. Galarza-Delgado¹, Iris Colunga¹, José Ramón Azpiri-López¹, Valeria Gonzalez-Gonzalez², Victor Beltran³, Angel Arias Peralta⁴, Jesus Alberto Cardenas-De la Garza⁵ and Rosa Arvizu-Rivera⁶, ¹Hospital Universitario UANL, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico
Background/Purpose: The atherogenic index of plasma (AIP) is a novel marker to identify cardiovascular disease. Recently, AIP was reported to be related to long-term cardiovascular…
Abstract Number: 1299 • ACR Convergence 2023
Rheumatoid Arthritis Patients Who Never Use a Biological During Their Disease Course Represent a Subgroup of Patients Likely to Achieve Sustained DMARD-free Remission
Judith Heutz¹, Pascal de Jong¹, Annette van der Helm-van Mil² and Elise van Mulligen¹, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: According to the 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) complete cessation of DMARDs is not advisable due to a high…
Abstract Number: 1315 • ACR Convergence 2023
Elevated Serum Adiponectin Levels During Olokizumab Treatment in Patients with Rheumatoid Arthritis Correlate with High-density Lipoprotein Lipid Profile Independently of Body Mass Index: Results from the Double-blind, Randomized Controlled Phase III Studies
Elena Zonova¹, Antonio Abbate², Eugen Feist³, Sergey Yakushin⁴, Maria Lemak⁵, Alina Egorova⁵, Daria Bukhanova⁵, Sergey Grishin⁵, Sofia Kuzkina⁵, Mikhail Samsonov⁶ and EVGENY NASONOV⁷, ¹Novosibirsk State Medical University, Novosibirsk, Russia, ²Robert M. Berne Cardiovascular Research Center, Charlottesville, VA, ³Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ⁴Ryazan State Medical University, Ryazan, Russia, ⁵R-Pharm, Moscow, Russia, ⁶RPharm, Moscow, Russia, ⁷Scientific Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Active rheumatoid arthritis (RA) is associated with a higher prevalence of insulin resistance (IR). Dysregulation of adipokines driven by low-level systemic inflammation plays a…
Abstract Number: 1332 • ACR Convergence 2023
Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)
Gerd Burmester¹, Patrick Verschueren², Jerome AVOUAC³, Roberto F. Caporali⁴, Karen Bevers⁵, Neil Betteridge⁶, Thomas P.A. Debray⁷, Francesco De Leonardis⁸, Susana Romero Yuste⁹, Monia Zignani⁸ and James Galloway¹⁰, ¹Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ⁵Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁶Neil Betteridge Associates, London, United Kingdom, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹⁰King's College London, London, United Kingdom
Background/Purpose: The efficacy of filgotinib (FIL) for treating RA has been demonstrated in clinical trials. Real-world data are valuable to assess patient-reported outcomes such as…
Abstract Number: 1356 • ACR Convergence 2023
Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Amaya Smole¹, Lucy Masto¹, Caroline Siegel¹, Sarah Lieber², Sanjana Adurty³, Jonah Levine¹, Bessie Stamm¹, Lisa Mandl², Michael Lockshin², Lisa Sammaritano² and Medha Barbhaiya², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Weill Cornell Medical College, New York, NY
Background/Purpose: Women with systemic rheumatic diseases (SRDs), particularly those with SLE, may be more vulnerable to HPV infection and HPV-related cervical cancer. However, HPV testing…
Abstract Number: 1678 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis
Xavier Sendaydiego¹, Laura Gold², Jean liew³, K Wysham⁴, Maureen Dubreuil⁵, James Andrews¹, Pankti Reid⁶, David Liew⁷, Radjiv Goulabchand⁸, Abha Singh⁹, Grant Hughes¹, Mathilde Pioro¹, Jeffrey Sparks¹⁰, Jeffrey Jarvik², Siddharth Singh⁹ and Namrata Singh¹¹, ¹University of Washington, Seattle, WA, ²Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, ³Boston University, Boston, MA, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁶University of Chicago Medical Center, Chicago, IL, ⁷Austin Health, Heidelberg, Australia, ⁸St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, ⁹University of California San Diego, San Diego, CA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: In the ORAL Surveillance trial, cancer risk was higher among patients with rheumatoid arthritis (RA) on tofacitinib, a Janus kinase inhibitor (JAKi), compared to…
Abstract Number: 1733 • ACR Convergence 2023
Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease
Nozima Aripova¹, Michael Duryee¹, Amy Nelson¹, Carlos Hunter¹, Breanna Butler¹, Bryant England¹, Jill Poole¹, Geoffrey Thiele¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a leading cause of mortality in RA with limited treatment options as well as lack of available…
Abstract Number: 1749 • ACR Convergence 2023
Fatty Acid Synthase Is a Critical Repressor of Ferroptosis in Rheumatoid Arthritis
Qi Cheng, Mo chen, Xin chen, Yifan Xie, Yan Du and Huaxiang wu, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with synovial inflammation as the main pathological feature, and can eventually lead to irreversible joint or…
Abstract Number: 1765 • ACR Convergence 2023
Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives
Jeba Maisha, Xiaobo Meng, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Cigarette smoking (CS) is a major environmental risk factor for the development of Rheumatoid Arthritis (RA), and is associated with the development of RA…
Abstract Number: 1853 • ACR Convergence 2023
Each Joint in a 28 Joint Count Is More Likely to Be Affected by Deformity/Limited Motion Than by Swelling in Rheumatoid Arthritis Patients with Long Disease Duration: Deformity/Limited Motion Should Be Included in Joint Counts Performed in Routine Care
Rahel Hunter¹, Nicholas Rodwell² and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Liverpool, Australia
Background/Purpose: The 28 joint count for rheumatoid arthritis (RA) was designed to recognize 3 abnormalities: swelling, (SWL), tenderness/pain on motion (TEN), and deformity/limited motion (DEF),…
Abstract Number: 1915 • ACR Convergence 2023
Scleritis and Development of Autoimmune Disease: A Case Series
Tessalyn Morrison¹, Moriah Gottman², Marcia Friedman³ and Daniela Ghetie⁴, ¹University of Vermont, Burlington, VT, ²Oregon Health & Science University, Milwaukie, OR, ³Alpine Immune Sciences, Inc., Beaverton, OR, ⁴Oregon Health & Science University, Portland, OR
Background/Purpose: Scleritis involves inflammation of the sclera caused by trauma, infections, or autoimmune conditions. The purpose of our study was to understand the relationship between…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].